Longitudinal prognostication in retroperitoneal sarcoma survivors: Development and external validation of two dynamic nomograms
Dario Callegaro(Fondazione IRCCS Istituto Nazionale dei Tumori), Alessandro Gronchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Carol J. Swallow(University Health Network), Rebecca A. Gladdy(Princess Margaret Cancer Centre), Rick L. Haas(Leiden University Medical Center), Rosalba Miceli(Fondazione IRCCS Istituto Nazionale dei Tumori), Frits van Coevorden(The Netherlands Cancer Institute), Deanna Ng(Mount Sinai Hospital), Francesco Barretta(Fondazione IRCCS Istituto Nazionale dei Tumori), Chandrajit P. Raut(Dana-Farber Cancer Institute), Sylvie Bonvalot(Dana-Farber Cancer Institute), D. Strauß(Royal Marsden Hospital), Charles Honoré(Institut Gustave Roussy), Winan J. van Houdt(Diakonessenhuis hospital), Nikolaos Vassos(European University Cyprus), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Mark Fairweather(Brigham and Women's Hospital), Lorenzo Conti(Fondazione IRCCS Istituto Nazionale dei Tumori), Eberhard Stoeckle(Institut Bergonié), Yvonne Schrage(The Netherlands Cancer Institute)
Cited by 32
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k